When Your Competitor Owns Your Factory: The Question Every Bar Brand Should Be Asking After the Barebells–EMPWR Deal

On July 2, 2026, Vitamin Well Group — the Swedish company behind Barebells — announced it was combining with EMPWR, the Belgian contract manufacturer that has produced Barebells bars for years. Waterland Private Equity, EMPWR's owner since 2017, will roll part of its proceeds into a minority stake. Cinven remains Vitamin Well's lead investor. The deal is expected to close in the fourth quarter of 2026.

The trade press covered it as a capacity story, and on Vitamin Well's side of the table, that's exactly what it is. Barebells has been growing faster than its supply chain could comfortably serve, and Cinven was refreshingly plain about the logic: the deal "unlocks the ability to increase investments in capacity and pursue significant volume growth opportunities." Jonas Pettersson called it a transformational moment. He's not wrong.

But there's a second story inside this one that nobody at the announcement had any reason to tell, and it belongs to a different set of people entirely.

EMPWR doesn't just make Barebells. It runs four plants across Croatia, the Netherlands, the United States and Canada, employs more than 1,500 people, and manufactures nutrition bars for more than 100 customers worldwide. Vitamin Well was already its largest. As of Q4, Vitamin Well will own it.

So if you're one of the other hundred-odd brands on that customer list, here is your new situation: the company that holds your formula, runs your line, knows your unit economics and sees your launch calendar nine months before your buyer does is now owned by a brand sitting three feet from you in the same set.

The quiet part

UK consultant Karl Bickley of Seventy8 Consulting wrote something on LinkedIn about this deal that I keep coming back to. When demand outruns supply, he said, owning the brand stops being enough — you want the production line, the capacity, the recipes, the margin that a booming protein market is making scarce.

The recipes. That word is doing an enormous amount of work, and I don't think it was a slip.

Here's what a co-manufacturer actually knows about you, and it's more than most founders realize until they write it down. Your full formula and every failed version of it. Your ingredient specs and which suppliers you qualified. Your cost per bar at every volume tier. Your yields and scrap rate — which is to say your real margin, not the one in your deck. Your forecast, by SKU, by month. Which of your SKUs is quietly dying. And your next launch, in detail, from the moment you brief the pilot run.

Under normal circumstances that asymmetry is fine, because it's mutual dependence: your co-man's business is your business. What changes when a competitor buys the plant isn't the NDA. It's the incentive structure sitting behind it.

Three exposures worth naming

Line time. This is the one that bites first, and it doesn't require anyone to behave badly. Capacity is genuinely scarce right now — whey pricing has been brutal and every bar plant in North America is running hotter than it was two years ago. When two runs want the same line on the same Tuesday, someone decides. If one of them belongs to the owner, that decision has a gravitational pull no contract language fully cancels.

Innovation. Cinven said the combination would "accelerate" new product development. Ask where NPD acceleration comes from at a contract manufacturer. Some is equipment and R&D headcount. A lot of it is pattern recognition across a hundred customers — which textures scale, which claims are showing up in briefs, what the market is asking for six months before it hits retail. Legitimately valuable knowledge, honestly developed. Also, now, an asset inside a competitor.

Capital allocation. New capex, the best formulator, the newest enrobing line, the capability nobody else in the region has — those get assigned by someone with a P&L to answer to. Investment follows ownership. It always has.

What the contract will and won't do for you

Real firewalls exist, and serious CDMOs take them seriously. EMPWR has said it will continue operating its third-party manufacturing business and honor existing customer commitments, and I'd expect that to be true — a hundred customers is a valuable book of business, and destroying it would be a strange way to celebrate a merger.

But be precise about what contractual protection covers. Confidentiality and IP ownership clauses govern documents and disclosures. They don't govern judgment. Nothing in your MSA determines which changeover gets scheduled first, which project gets the best R&D person, or which of two customers hears "we can't take that volume until March."

And there's a specific trap in bar manufacturing that founders miss constantly: owning your formula is not the same as owning your process. The ingredient deck and ratios may be yours on paper. The run parameters — mixer speeds, temperatures, dwell times, cooling profile, the twenty small corrections that made batch nine work when one through eight didn't — often live with the manufacturer as process know-how. Brands discover this a week into an emergency tech transfer.

This isn't an anomaly. It's the direction.

Bar manufacturing is consolidating on both sides at once. Mubadala Capital combined TruFood Manufacturing with Bar Bakers. Mondelez owns Clif. Kellanova owns RXBAR. And below the headline level, plenty of co-packers quietly run house brands or private label in the same categories they manufacture for — private label is now roughly a quarter of US retail food and beverage dollars, and no disclosure standard requires anyone to tell you what else comes off your line.

The deal doesn't close until Q4. If you're on that customer list, this is the window — the rare moment when you can ask hard questions before the answers are somebody else's to give.

Thinking about a second source, a formula you can actually take with you, or a partner whose interests don't sit across the aisle from yours? That's the conversation our Innovation Center exists for. Get in touch.